Imago BioSciences to be acquired by Merck (MRK) for $36.00/share
- Cos announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Imago for $36.00 per share in cash for an approximate total equity value of $1.35 billion.
- “This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of hematology,” said Merck Chief Executive Robert Davis in a news release.
- Hematology is the branch of medicine that focuses on the study of blood diseases. Imago is a clinical stage biopharmaceutical company developing new medicines for the treatment of several bone marrow diseases.
No comments:
Post a Comment